Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

Ying Jiang(Beijing Hospital), Ralph A. Nixon(Nathan Kline Institute for Psychiatric Research), John Alam(Hispanics in Philanthropy), Philip Scheltens(Amsterdam Neuroscience), Afina W. Lemstra(Amsterdam UMC Location VUmc), John F. Smiley(Nathan Kline Institute for Psychiatric Research), Niels D. Prins, Stephen N. Gomperts(Harvard University), Shivakumar Subbanna(Nathan Kline Institute for Psychiatric Research), Sandipkumar Darji(Nathan Kline Institute for Psychiatric Research), Philip Stavrides(Nathan Kline Institute for Psychiatric Research), John Harrison(Amsterdam Neuroscience), Sandeep Malampati(Nathan Kline Institute for Psychiatric Research), Cynthia Bleiwas(Nathan Kline Institute for Psychiatric Research), Monika Pawlik(Nathan Kline Institute for Psychiatric Research), Paul Maruff(Florey Institute of Neuroscience and Mental Health), Amanda Gardner, Charlotte E. Teunissen(Amsterdam UMC Location Vrije Universiteit Amsterdam), James Peddy(Nathan Kline Institute for Psychiatric Research), Ursula A. Germann, Balapal S. Basavarajappa(Nathan Kline Institute for Psychiatric Research), Anna Pensalfini(Nathan Kline Institute for Psychiatric Research), Dun‐Sheng Yang(Nathan Kline Institute for Psychiatric Research), Hui‐May Chu, Kelly Blackburn
Nature Communications
September 21, 2022
Cited by 58


Related Papers